SCHEMBL2236908

SCHEMBL2236908

COC(=O)Oc1cc[c]cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 5/20 0.41
MAPT P10636 4/20 0.41
HSD17B10 Q99714 3/20 0.41
HTT P42858 3/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 2/20 0.40
HPGD P15428 1/20 0.40
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP14 P50281 1/20 0.39
ELANE P08246 2/20 0.36
RAB9A P51151 1/20 0.35
GAA P10253 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
JAK2 O60674 1/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL676909 0.84 KMT2A (0.58) KMT2AMEN1ALDH1A1MAPTHSD17B10
SCHEMBL8942876 0.78 TDP1 (0.44) KMT2AMEN1ALDH1A1MAPTHSD17B10
SCHEMBL486023 0.78 ELANE (0.62) KMT2AMEN1MAPTHTTELANE
SCHEMBL5731400 0.78 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1MAPTLMNA
SCHEMBL697317 0.77 CA1 (0.56) KMT2AMEN1ALDH1A1HTTLMNA
SCHEMBL27496383 0.77 HPGD (0.57) KMT2AMEN1ALDH1A1MAPTHSD17B10
SCHEMBL6936328 0.77 MMP2 (0.55) KMT2AMEN1ALDH1A1MAPTHSD17B10
SCHEMBL8779173 0.77 KMT2A (0.52) KMT2AMEN1ALDH1A1MAPTHSD17B10
SCHEMBL29250 0.77 HPGD (0.57) KMT2AMEN1ALDH1A1MAPTHSD17B10
SCHEMBL128884 0.77 LMNA (0.58) KMT2AMEN1ALDH1A1MAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020196666-A1 POLYOL BLEND LIQUID FOR PRODUCING HALOALKENE POLYURETHANE FOAM 東ソー株式会社 2020-10-01 WO disclosed
EP-2354123-B1 NOVEL SULFONIUM BORATE COMPLEX DEXERIALS CORP (JP) 2015-02-25 EP disclosed
US-8877878-B2 Epoxy resin composition with sulfonium borate complex DEXERIALS CORPORATION (JP) 2014-11-04 US disclosed
US-8710662-B2 Light-reflective anisotropic conductive paste and light-emitting device Sony Corporation & Information Device Corporation (JP) 2014-04-29 US disclosed
EP-2581955-A1 LIGHT-REFLECTIVE ANISOTROPIC ELECTRICALLY CONDUCTIVE PASTE, AND LIGHT-EMITTING DEVICE Sony Chemical & Information Device Corporation (JP) 2013-04-17 EP disclosed
US-20120248495-A1 LIGHT-REFLECTIVE ANISOTROPIC CONDUCTIVE PASTE AND LIGHT-EMITTING DEVICE SONY CHEMICAL & INFORMATION DEVICE CORPORATION (JP) 2012-10-04 US disclosed
US-20110192639-A1 NOVEL SULFONIUM BORATE COMPLEX SONY CHEMICAL & INFORMATION DEVICE CORPORATION (JP) 2011-08-11 US disclosed
EP-2354123-A1 NOVEL SULFONIUM BORATE COMPLEX Sony Chemical & Information Device Corporation (JP) 2011-08-10 EP disclosed
US-7820355-B2 Radiation sensitive resin composition ZEON CORPORATION (JP) 2010-10-26 US disclosed
EP-1043021-B1 PURINE DERIVATIVES FOR THE TREATMENT OF ALLERGIC DISEASES AND SYSTEMIC LUPUS ERYTHEMATOSUS DAINIPPON SUMITOMO PHARMA CO (JP) 2006-05-03 EP disclosed
US-6376501-B1 INHIBITING OR REGULATING IMMUNE RESPONSE USING PURINE-DERIVED COMPOUND; NON-STEROIDAL COMPOUND JAPAN ENERGY CORPORATION (JP) 2002-04-23 US disclosed
US-6310070-B1 FOR TREATING NEPHRITIS, IMPROVING PROTEINURIA DUE TO GLOMERULONEPHRITIS AND PREVENTING AGGRAVATION OF NEPHRITIS JAPAN ENERGY CORPORATION (JP) 2001-10-30 US disclosed
EP-1043021-A1 TYPE 2 HELPER T CELL-SELECTIVE IMMUNE RESPONSE SUPPRESSORS Japan Energy Corporation (JP) 2000-10-11 EP disclosed
EP-0999211-A1 NOVEL PURINE DERIVATIVES AND MEDICINAL USE THEREOF JAPAN ENERGY CORPORATION (JP) 2000-05-10 EP disclosed
US-6028076-A FOR INDUCING .ALPHA.-INTERFERON IN A PATIENT HAVING HEPATITIS B OR C, BY ADMINISTERING PURINE DERIVATIVE JAPAN ENERGY CORPORATION (JP) 2000-02-22 US disclosed
EP-0882727-A1 NOVEL PURINE DERIVATIVES JAPAN ENERGY CORPORATION (JP) 1998-12-09 EP disclosed
EP-0324431-B1 NEW INDOLYLPIPERIDINE COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-03-25 EP disclosed
US-5017703-A Antiallergens, antiinflammatory FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1991-05-21 US disclosed
US-4935432-A ANTIALLERGENS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-06-19 US disclosed
EP-0324431-A1 New indolylpiperidine compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110192639-A1 NOVEL SULFONIUM BORATE COMPLEX EBPL, ITGB1, ITGA1 KMT2A 2179/4885MEN1 2130/4885ALDH1A1 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.